RxDoctor Payments Data

Christopher Peterson, MD

MOHS-Micrographic Surgery · Greenville, SCNPI 1609891472

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $928 of the $1,397 with a category attached, or 66.4%. 18 manufacturers reported payments, led by Johnson & Johnson at 43.7% of the total. Reporting peaked in 2023 at $395 and has fallen 74.1% since, to $102 in 2025. That places this record below the midpoint for mohs-micrographic surgery clinicians in SC, where the typical reported total is $2,794.

$1,397in general payments, 2019–2025

Across 56 payments — averaging $24.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$610
  • Genentech USA, Inc.$117
  • E.r. Squibb & Sons, L.L.C.$115
  • AbbVie$97
  • Incyte Corporation$74
  • Novartis$55
  • plus $329 from 12 others

What the payments were for

  • Food & beverage$92866%
  • Education$46934%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,397 in reported general payments places this provider in the 30th percentile of 22 mohs-micrographic surgery providers in South Carolina.

See all mohs-micrographic surgery providers in South Carolina

Medicare billing

Part B allowed, 2024
$1,282,018
Medicare patients
1,690
Services billed
10,646

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab55$236,251
Cosentyx (2 Syringes)Secukinumab12$102,270
Enbrel SureclickEtanercept13$92,823
Fluorouracil168$10,139
Mupirocin1,216$7,275
Ketoconazole419$5,826
Triamcinolone Acetonide423$4,464
Acitretin20$3,538
Tacrolimus16$3,202
Metronidazole44$1,790
Nystatin153$1,647
Clobetasol Propionate40$1,372
Cephalexin395$1,287
Ammonium Lactate42$985
Minocycline Hcl75$954

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisCosentyx (2 Syringes)$55$102,27012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 22 mohs-micrographic surgery providers in South Carolina.

Other mohs-micrographic surgery in Greenville

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →